| Dosing: 1-2 drops twice daily
Supplied: [0.25% susp , 0.5% soln]
|Dosing: 1 drop twice daily.
Supplied: [1% soln]
| Dosing: 1-2 drops once or twice daily.
Supplied: [0.25 & 0.5% soln]
| Dosing: drop twice daily. Supplied: [soln 0.25 & 0.5%].
Timoptic XE: 1 drop once daily. Supplied: [0.25 & 0.5% gel]
|Indications: the treatment of primary open-angle glaucoma and also to lower intraocular pressure prior to surgery for acute angle-closure glaucoma. It may be used in combination with other miotics, beta adrenergic blocking agents, carbonic anhydrase inhibitors, hyperosmotic agents, or epinephrine.
Dosing: 1-2 drops 3 to 4 times daily or ½” gel at bedtime.
|Dosing: Instill one drop in the affected eye(s) once daily in the evening. The dosage should not exceed once daily since it has been shown that more frequent administration may decrease the intraocular pressure lowering effect. [Supplied: 0.03% soln]|
|Dosing: 1 drop at bedtime.
Supplied: [soln: 0.005 %]
|INDICATIONS AND USAGE:
ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
USE IN SPECIFIC POPULATIONS
DOSAGE AND ADMINISTRATION:
DOSAGE FORMS AND STRENGTHS:
WARNINGS AND PRECAUTIONS
|Dosing: Instill one drop in the affected eye(s) once-daily in the evening. The dosage of TRAVATAN® should not exceed once-daily since it has been shown that more frequent administration may decrease the intraocular pressure lowering effect. [Supplied: 0.004% solution]|
|Dosing: Instill one drop in the affected eye(s) twice daily. RESCULA ® may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If two drugs are used, they should be administered at least five minutes apart. Structural analogue of an inactive biosynthetic cyclic derivative of arachidonic acid. [ Supplied: 0.15% solution ]|
| Dosing: 1-2 drops three times daily.
Supplied: [ soln: 0.5, 1%]
| Dosing: 1 drop three times daily.
Supplied: [soln: 0.2%]
|Dosing: 1 drop twice daily.|
|Dosing: 1 drop twice daily.
Supplied: [soln: 0.1%]
|SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%|
|SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%
[Drug information / PDF]
Dosing: Click (+) next to Dosage and Administration section (drug info link)Initial U.S. Approval: 2013
Mechanism of Action: SIMBRINZA is comprised of two components: brinzolamide (carbonic anhydrase inhibitor) and brimonidine tartrate (alpha 2 adrenergic receptor agonist). Each of these two components decreases elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage.
Brinzolamide inhibits carbonic anhydrase in the ciliary processes of the eye to decrease aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Brinzolamide has a peak ocular hypotensive effect occurring at 2 to 3 hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Brimonidine tartrate has a peak ocular hypotensive effect occurring at two hours post-dosing. The result is a reduction in intraocular pressure (IOP).
INDICATIONS AND USAGE: SIMBRINZA is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
HOW SUPPLIED: Suspension containing 10 mg/mL brinzolamide and 2 mg/mL brimonidine tartrate.
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer